Exploratory Study of the Diagnostic Potential of an Innovative Thoracic Vibration Analysis Technique (AIRFORCE2)

Caen University Hospital

Status: Enrolling

Conditions: Cardiac Disease, Pulmonary Disease

Treatments: Device: SMC signal recording

Study type: Interventional

Funder types: Other

Identifiers

NCT06661200

2023-A02696-39

Details and patient eligibility

About

Heart and lung disease are two major causes of hospitalisation and mortality in France (4-8). Together, these two diseases affect several million people in France, either acutely or chronically. They represent a major public health problem in social and economic terms.

Diagnosis of these disorders is often delayed, with acute decompensation preceded by a period of frustrating, non-specific clinical signs (9-12), which delay their discovery. Screening for these conditions in their early stages or diagnosing them in their acute form is crucial, but remains difficult because it requires multiple investigations that are costly and time-consuming (biology, radiology, ECG, etc.). The difficulty of diagnosis, the progressive profile and the ever-increasing frequency of these conditions (environmental and socio-economic factors) have considerably altered the landscape of medical emergencies and contributed to their difficulty.

The availability of a non-invasive technique capable of diagnosing both cardiac and pulmonary disorders without the help of an expert, without direct contact with the patient and without requiring his or her active participation, would be a major advance.

Technological innovations in all fields have always helped to improve patient care.The recent emergence of telemedicine and POCT(US) connected objects (point of care testing, point of care ultrasound)(13,14) is a good illustration of this.

A new technique using ultrasound, developed by the Langevin Institute (Surface Camera Motion) and supported by the start-up Austral Diagnostics, makes it possible, without direct contact with the subject, to record the propagation of thoracic vibrations induced by the functioning of the heart pump and respiratory mechanics.Consequently, any anomaly in the functioning of these organs can cause a change in the thoracic vibration regime and its propagation.

This completely new technique for exploring thoracic vibrations provides a particularly rich signal that has not yet been explored. Under these conditions, the signatures associated with cardiac and/or pulmonary pathologies are not yet perfectly defined.Furthermore, the diagnostic potential of this new technique in the early or acute phases of cardiopulmonary pathologies remains to be assessed.

In this prospective study, we propose to explore the signatures produced by this signal in various cardiac and respiratory pathologies.

The aim is To identify the discriminating criteria of the SMC signal that enable cardiac and pulmonary pathologies to be detected compared with a group of healthy subjects.

Enrollment: 270 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Cardiac disease OR respiratory failure OR healthy volunteer
• Affiliate to the social security system
• French-speaking
• Patient having been informed of the study and having signed informed

Exclusion criteria

• consent.BMI < 17 or BMI > 35
• Patients unable to stand for more than 10 minutes
• Patients unable to remain in apnea for 15 - 20 seconds
• Breast prosthesis wearers
• Wearers of pacemakers and/or defibrillators
• Valve prosthesis wearers
• Patients with difficulty understanding simple instructions (inspiration, expiration, respiratory blockage)
• Patients with severe hearing problems.
• Pregnant or breastfeeding woman. A urine pregnancy test will be performed if necessary.

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

270 participants in 3 patient groups

Healthy subjects N = 70 no cardiac and no pulmonary disease

Experimental group

Description:

Healthy subjects who should undergo SMC recording after echocardiography and resporatory exploration.

Treatment:

Device: SMC signal recording

Cardiac disease group

Experimental group

Description:

Patients in this group had heart disease (n = 150): (i) aortic stenosis (ii) aortic leakage (iii) mitral leakage (iv) dilated cardimyopathy (v) or restrictive cardiomyopathy.

Treatment:

Device: SMC signal recording

Respiratory failure

Experimental group

Treatment:

Device: SMC signal recording